A phase 3 trial evaluating panitumumab plus best supportive care vs best supportive care in chemorefractory wild-type KRAS or RAS metastatic colorectal cancer.

导出 OA

翻译打印收藏纠错

作者： Tae Won,Kim ^[1] ; Anneli,Elme ^[2] ; Zvonko,Kusic ^[3] ; Joon Oh,Park ^[4] ; Anghel Adrian,Udrea ^[5] ; Sun Young,Kim ^[6] ; Joong Bae,Ahn ^[7] ; Ricardo Villalobos,Valencia ^[8] ; Srinivasan,Krishnan ^[9] ; Ante,Bilic ^[10] ; Nebojsa,Manojlovic ^[11] ; Jun,Dong ^[12] ; Xuesong,Guan ^[12] ; Catherine,Lofton-Day ^[12] ; A Scott,Jung ^[12] ; Eduard,Vrdoljak ^[13]

作者单位： Department of Oncology, Asan Medical Center, University of Ulsan, Seoul 138-736, South Korea. ^[1] North Estonia Medical Centre Foundation, Tallinn 13419, Estonia. ^[2] University Hospital Center 'Sestre Milosrdnice', Zagreb 10000, Croatia. ^[3] Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul 135-710, South Korea. ^[4] MEDISPROF, Cluj-Napoca 400367, Romania. ^[5] National Cancer Center, Goyang-si, Gyeonggi-do 410-769, South Korea. ^[6] Yonsei University Health System Severance Hospital, Seoul 120-752, South Korea. ^[7] Centro Medico Nacional Siglo XXI, Mexico City 06725, Mexico. ^[8] Dr Rai Memorial Medical Centre, Chennai 600018, India. ^[9] Klinicka bolnica Sveti Duh, Zagreb 10000, Croatia. ^[10] Clinic for Gastroenterology and Hepatology of Military Medical Academy of Serbia, Belgrade 11000, Serbia. ^[11] Amgen Inc., Thousand Oaks, CA 91320, USA. ^[12] Department of Oncology, Center of Oncology, Clinical Hospital Center Split, Split 21000, Croatia. ^[13]